Quadrant Capital Group LLC Reata Pharmaceuticals Inc Transaction History

Quadrant Capital Group LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$79.22 - $105.37 $7,367 - $9,799	-93 Reduced 34.7%	175 $17,000
Q4 2022 Feb 10, 2023	SELL	$22.15 - $42.11 $376 - $715	-17 Reduced 5.96%	268 $10,000
Q3 2022 Nov 10, 2022	SELL	$19.41 - $36.49 $108,696 - $204,344	-5,600 Reduced 95.16%	285 $7,000
Q2 2022 Aug 09, 2022	SELL	$20.71 - $36.5 $414,137 - $729,890	-19,997 Reduced 77.26%	5,885 $179,000
Q1 2022 May 06, 2022	BUY	$24.12 - $39.6 $141,246 - $231,897	5,856 Added 29.24%	25,882 $848,000
Q4 2021 Feb 01, 2022	BUY	$25.61 - $110.96 $512,532 - $2.22 Million	20,013 Added 153946.16%	20,026 $528,000
Q2 2021 Aug 09, 2021	BUY	$78.27 - $151.29 $234 - $453	3 Added 30.0%	13 $2,000
Q1 2021 May 12, 2021	SELL	$94.25 - $132.81 $1,413 - $1,992	-15 Reduced 60.0%	10 $1,000
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $1,530 - $2,769	15 Added 150.0%	25 $3,000
Q3 2020 Nov 13, 2020	SELL	$93.53 - $163.34 $561 - $980	-6 Reduced 37.5%	10 $1,000
Q2 2020 Aug 13, 2020	BUY	$126.3 - $176.56 $2,020 - $2,824	16 New	16 $2,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.